Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424259 | 0.89 | NAMPT (0.45) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL12108433 | 0.87 | LMNA (0.61) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3436956 | 0.86 | LMNA (0.69) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL13923290 | 0.86 | LMNA (0.64) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL22874778 | 0.83 | LMNA (0.49) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL12384643 | 0.82 | LMNA (0.47) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL13923289 | 0.81 | CHRNB2 (0.59) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL4198735 | 0.81 | LMNA (0.50) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL8916596 | 0.81 | MAPK1 (0.64) | LMNAHTTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3990839 | 0.81 | LMNA (0.50) | LMNAHTTSMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | LMNA 1043/4885HTT 2128/4885SMN1; SMN2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.